



Primary IR Contact

Investor Relations and Public Affairs

Phone: 650-837-8194

Fax: 650-837-8205

E-mail: shubbard@exelixis.com

Corporate Profile

Founded in 1994, Exelixis, Inc. (NASDAQ: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally. We are steadfast in our commitment to prudently reinvest in our business to maximize the potential of our pipeline. We intend to supplement our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. Exelixis recently earned a spot on Deloitte's Technology Fast 500 list, a yearly award program honoring the 500 fastest-growing companies over the past four years.

Recent Headlines

11/15/18

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) Tablets for the Treatment of Hepatocellular Carcinoma in Adults Previously Treated with Sorafenib

11/06/18

Exelixis to Present at the Stifel 2018 Healthcare Conference on November 13, 2018

11/01/18

Exelixis Announces Third Quarter 2018 Financial Results and Provides Corporate Update

Upcoming Events

There are currently no events scheduled.

Stock Performance

EXEL (Common Stock)

Exchange NASDAQ (US Dollar)

Price \$17.92

Change (%) 0.00 (0.00%)

Volume 436

52 Week Low \$13.42

Market Cap \$5,357,777,779

Rolling EPS 1.18

PE Ratio 15.2149

Shares Outstanding 298,983,135

Data as of 11/16/18 4:00 p.m. ET



Analyst Estimates / Ratings

Mean Recommendation: 2.1



Sell

Strong Buy

Unable to fulfill request.

SEC Filings

Filing Date	Form	Description	Filing Group
11/16/18	4	Statement of changes in beneficial ownership of securities	3,4,5
11/16/18	4	Statement of changes in beneficial ownership of securities	3,4,5
11/16/18	4	Statement of changes in beneficial ownership of securities	3,4,5

Corporate Governance

Michael Morrissey, Ph.D.	President and Chief Executive Officer
Gisela M. Schwab, MD	President, Product Development and Medical Affairs and Chief Medical Officer
Christopher J. Senner	Executive Vice President and Chief Financial Officer
Dana Aftab Ph.D.	Executive Vice President, Business Operations
Laura Dillard	Senior Vice President, Human Resources
P.J. Haley, MBA	Senior Vice President, Commercial
Jeffrey J. Hessekiel, J.D.	Executive Vice President and General Counsel
Susan Hubbard	Executive Vice President, Public Affairs and Investor Relations
Peter Lamb, Ph.D.	Executive Vice President, Scientific Strategy and Chief Scientific Officer

Ownership Summary

Shareholders

	Holders	Value (\$MM)	% O/S	Shares
Institution	451	4,339.87	80.9	241,960,892
Mutual Fund	519	2,414.33	45.4	135,596,675
Insider *	16	86.78	1.6	4,767,806

*Insider values reflect direct beneficial ownership.

Top Holders

	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	27,749,354	9.3	1,125,910	09/30/18
The Vanguard Group, Inc.	26,527,089	8.9	834,478	09/30/18
Fidelity Management & Research Company	24,514,314	8.2	-4,398,820	09/30/18
Meditor Capital Management Limited	15,966,038	5.3	0	09/30/18
State Street Global Advisors (US)	11,282,667	3.8	679,083	09/30/18
Matrix Capital Management Company, LLC	10,000,000	3.3	0	09/30/18
Merian Global Investors (UK) Limited	4,666,961	1.6	995,133	09/30/18
First Trust Advisors L.P.	4,643,726	1.6	2,044,201	09/30/18

Data provided by Nasdaq. Minimum 15 minutes delayed.